Assessing the Benefit of Higher Biologically Effective Dose in Patients With Squamous Cell Carcinoma of the Lung Treated With Stereotactic Body Radiation Therapy.

J S Parzen,M F Almahariq,T J Quinn,Z A Siddiqui,A Thompson,T M Guerrero,K C Lee,C W Stevens,I S Grills

International journal of radiation oncology, biology, physics（2021）

引用 0|浏览4

暂无评分

摘要

Our analysis suggests that in patients with early-stage NSCLC, SBRT regimens employing the use of BED > 150 Gy may confer a survival benefit in patients with SCC histology. Histology-based dose modification should be considered, and prospective validation may be warranted.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要